Hematology Frontier

The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13 to 16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world to share and discuss innovative ideas and the latest scientific and clinical research findings in hematology. At this year's conference, a study by Professor Yang Liang's team from Sun Yat-sen University Cancer Center on "Bone Marrow Ecosystem Formation and Secondary Resistance to Anti-CD38 Therapy in Multiple Myeloma" was selected for an oral presentation (S198). This study provides significant insights and references for optimizing resistance management in anti-CD38 therapy for multiple myeloma. We invited Professor Yang Liang for an interview to delve into the study's content and its clinical implications, as well as to highlight future research directions in this field.

The 29th Annual Meeting of the European Hematology Association (EHA) was grandly held from June 13 to 16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world every year to share and discuss innovative ideas and the latest scientific and clinical research results in hematology. At this year's conference, a study by Professor Liang Wang's team from Beijing Tongren Hospital, Capital Medical University, was selected for poster presentation (P1187). The study, based on a PRISMA-compliant meta-analysis and systematic review, explored the best treatment options for vitreoretinal lymphoma (VRL). To provide a better understanding of the research findings, "Oncology Frontier - Hematology Frontier" invited the first author of the study, Dr.  Jing Gao, to introduce the research in detail and Professor Liang Wang to provide an in-depth commentary.

The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13 to 16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world each year to share and discuss innovative ideas and the latest scientific and clinical research findings in hematology. At this year's conference, a study by Dr. Fang Xu from Prof. Yue Lu's team at Beijing Lu Daopei Hospital was selected for poster presentation (P1299). The study compared the application of ATG-T vs. ATLG in TBI-based conditioning for alternative donor allogeneic hematopoietic stem cell transplantation. We invited Dr. Fang Xu to introduce the study and provide insights for clinical practice or future research.

The 29th Annual Congress of the European Hematology Association (EHA) took place from June 13 to 16, 2024, in Madrid, Spain. Renowned as the "Olympics" of European hematology, the EHA Congress is celebrated for its cutting-edge scientific discussions and extensive clinical research findings, drawing global attention. Among the numerous highlights of this year's event was the EHA-CSH Joint Symposium, which brought together leading experts from China and Europe to discuss the latest advancements in T-cell acute lymphoblastic leukemia (T-ALL). Oncology Frontier – Hematology Frontier had the privilege of interviewing Professor Jianxiang Wang, co-chair of the symposium and Chief Clinical Expert at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, to share his insights on the event, key highlights of the EHA-CSH symposium, and his own research presentations and future directions.

The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13 to 16, 2024, in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world to share and discuss innovative ideas and the latest scientific and clinical research findings in hematology. At this year's conference, Professor Zhihui Li from Beijing GoBroad Boren Hospital presented research on the "Safety and Efficacy of Luspatercept in Allogeneic Transplantation for Malignant Hematologic Diseases." This study provides valuable insights for clinical practice. Oncology Frontier - Hematology Frontier had the opportunity to interview Dr. Zhihui Li at the conference to delve into the study's findings and their clinical implications.

The 29th European Hematology Association (EHA) Annual Meeting took place from June 13-16, 2024, in Madrid, Spain. At this prestigious event, Professor Huilai Zhang's team from Tianjin Medical University Cancer Institute and Hospital presented several research studies in poster sessions, highlighting the clinical features, genetic variations, and histological grading of follicular lymphoma. Their work offers a deeper understanding of the disease. Additionally, Professor Zhang's team delved into the epidemiological characteristics and prognosis of primary gastrointestinal follicular lymphoma, providing new insights for diagnosing and treating this rare disease. In the field of mantle cell lymphoma (MCL) treatment, their study on the Orelabrutinib-Lenalidomide-Rituximab regimen brings new hope to patients. Of particular note is their research on the impact of CD58 genetic alterations in diffuse large B-cell lymphoma (DLBCL), which enhances our understanding of the tumor immune microenvironment and suggests new approaches for personalized treatment. To provide a comprehensive overview of these research findings,Oncology Frontier - Hematology Frontier invited Professor Huilai Zhang to share the details.

Chronic myeloid leukemia (CML) has a reliable prognostic scoring system during the chronic phase, but blast phase (BP) lacks comprehensive analysis of prognostic factors or standardized scoring systems. Despite the era of tyrosine kinase inhibitors (TKIs), outcomes for BP patients remain poor. From June 13 to 16, 2024, the 29th European Hematology Association (EHA) Annual Congress was held in Madrid, Spain. At the congress, based on data from CML-BP patients diagnosed across multiple countries, the European Leukemia Network established a prognostic scoring system for BP-CML, clearly stratifying CML-BP patients into three distinct survival groups. Hematology Frontier is honored to feature commentary from Professor Bingcheng Liu, Director of the Leukemia Diagnosis and Treatment Center at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, on this study.

The treatment journey for Myelodysplastic Syndromes (MDS) is fraught with challenges due to its heterogeneity, hematopoietic failure, complications, and transformation risks, all of which significantly complicate therapy. Notably, the 29th Annual Meeting of the European Hematology Association (EHA 2024), held from June 13 to 16, 2024, showcased significant progress in the field of MDS treatment. In this issue of "Oncology Frontier - Hematology Frontier," we have invited Professor Zonghong Shao from Tianjin Medical University General Hospital to provide an in-depth introduction and commentary on key research in the MDS treatment domain. We hope Professor Shao's insightful sharing will reveal the latest developments in the MDS field, aiding our colleagues in grasping the forefront of treatment and jointly seeking better therapeutic options for MDS patients.

Mantle Cell Lymphoma (MCL) is a type of B-cell non-Hodgkin lymphoma (B-NHL) characterized by both the rapid progression of aggressive lymphomas and the incurability of indolent lymphomas, resulting in generally poor prognosis. At the recent "2024 Nanjing Lymphoma Forum," Professor Zhitao Ying from the Cancer Hospital of the Chinese Academy of Medical Sciences delivered an enlightening lecture titled "Advances in Diagnosis and Treatment of Mantle Cell Lymphoma." This article aims to provide a comprehensive overview of the current treatment landscape and emerging strategies for improving outcomes in MCL, as presented by Professor Ying.

Currently, the field of pediatric leukemia treatment faces numerous challenges, particularly in predicting relapse risk and developing treatment strategies for relapsed and refractory patients. At the upcoming 29th European Hematology Association (2024 EHA) Annual Meeting, several studies from Professor Xiaofan Zhu’s team from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences have been selected. Two studies on pediatric leukemia delve into these critical issues, providing important academic references for further optimizing pediatric leukemia diagnosis and treatment. To better understand these latest research advances, this issue of "Oncology Frontier - Hematology Frontier" features a detailed interpretation by Professor Xiaofan Zhu.